TCM
CYTK icon

Timpani Capital Management’s Cytokinetics CYTK Stock Holding History

Timpani Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-67,551
Closed -$868K – 97
2017
Q1 		$868K Buy
+67,551
New +$790K 0.35% 85

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Timpani Capital Management's CYTK Position: Q2 2017 in Review

Timpani Capital Management sold out of Cytokinetics (CYTK) in Q2 2017, closing a stake of 67,551 shares — an estimated $868K sold.

Timpani Capital Management first reported a position in CYTK in Q1 2017 and held it in 1 quarter. The position peaked at $868K in Q1 2017. 136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

  • Timpani Capital Management reported no remaining Cytokinetics position as of Q2 2017 after selling out during the quarter.
  • Timpani Capital Management sold 67,551 Cytokinetics shares in Q2 2017, an estimated $868K.
  • Timpani Capital Management first reported a position in Cytokinetics in Q1 2017 and held it in 1 quarter.
  • Timpani Capital Management's Cytokinetics position peaked at $868K in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on Timpani Capital Management's 13F filing for Q2 2017, filed 10 Aug 2017.